Dual effect of cAMP agonist on ameliorative function of PKA inhibitor in morphine-dependent mice

Fundamental and Clinical Pharmacology

Volumn 28, Issue 4, 2014, Pages 445-454

  Seyedi, Seyedeh Y ^a   Salehi, Forouz ^a   Payandemehr, Borna ^a   Hossein, Sara ^b   Hosseini Zare, Mahshid S ^a   Nassireslami, Ehsan ^a   Yazdi, Behnoosh B ^a   Sharifzadeh, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

cAMP; cGMP; GABA; Morphine dependence; NMDA; Protein kinase A; Withdrawal syndrome

Indexed keywords

BUCLADESINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MORPHINE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NALOXONE; ISOQUINOLINE DERIVATIVE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; NARCOTIC ANTAGONIST; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLIMBING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME INHIBITION; FOREFOOT; GROOMING; JUMPING; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REARING; TREMOR; WITHDRAWAL SYNDROME; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; PATHOPHYSIOLOGY; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALS; BUCLADESINE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ISOQUINOLINES; MALE; MICE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME; SULFONAMIDES;

EID: 84904039506     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12045     Document Type: Article

References (75)

1. Hamdy M.M., Mamiya T., Noda Y. et al. A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice. Behav. Brain Res. (2001) 118 85-93.
2. Itoh A., Shiotani T., Nakayama S. et al. Attenuation of the development of morphine dependence/tolerance by nefiracetam: involvement of adenosine 3′:5′-cyclic monophosphate system. Behav. Brain Res. (2000) 115 65-74.
3. Kimura M., Tokumura M., Itoh T., Inoue O., Abe K. Lack of cyclic AMP-specific phosphodiesterase 4 activation during naloxone-precipitated morphine withdrawal in rats. Neurosci. Lett. (2006) 404 107-111.
4. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci. (1991) 48 1991-2003.
5. Sharma S.K., Nirenberg M., Klee W.A. Morphine receptors as regulators of adenylate cyclase activity. Proc. Natl. Acad. Sci. USA (1975) 72 590-594.
6. Benalal D., Bachrach U. Opiates and cultured neuroblastoma x glioma cells. Effect on cyclic AMP and polyamine levels and on ornithine decarboxylase and protein kinase activities. Biochem. J. (1985) 227 389-395.
7. Traber J., Gullis R., Hamprecht B. Influence of opiates on the levels of adenosine 3′:5′-cyclic monophosphate in neuroblastoma X glioma hybrid cells. Life Sci. (1975) 16 1863-1868.
8. Collier H.O. Cellular site of opiate dependence. Nature (1980) 283 625-629.
9. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science (1997) 278 58-63.
10. Datta S. Activation of pedunculopontine tegmental PKA prevents GABAB receptor activation-mediated rapid eye movement sleep suppression in the freely moving rat. J. Neurophysiol. (2007) 97 3841-3850.
11. Jancic D., Lopez de Armentia M., Valor L.M., Olivares R., Barco A. Inhibition of cAMP response element-binding protein reduces neuronal excitability and plasticity, and triggers neurodegeneration. Cereb. Cortex (2009) 19 2535-2547.
12. Poisbeau P., Cheney M.C., Browning M.D., Mody I. Modulation of synaptic GABAA receptor function by PKA and PKC in adult hippocampal neurons. J. Neurosci. (1999) 19 674-683.
13. Westphal R.S., Tavalin S.J., Lin J.W. et al. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science (1999) 285 93-96.
14. El-Kadi A.O., Sharif S.I. Modification by muscimol of naloxone-precipitated withdrawal symptoms in morphine-dependent mice. Gen. Pharmacol. (1995) 26 1579-1581.
15. Marek P., Ben-Eliyahu S., Vaccarino A.L., Liebeskind J.C. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res. (1991) 558 163-165.
16. Shaw-Lutchman T.Z., Barrot M., Wallace T. et al. Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. J. Neurosci. (2002) 22 3663-3672.
17. Azami K., Etminani M., Tabrizian K. et al. The quantitative evaluation of cholinergic markers in spatial memory improvement induced by nicotine-bucladesine combination in rats. Eur. J. Pharmacol. (2010) 636 102-107.
18. Zamani M.J., Sharifzadeh M., Rezaie A., Mashayekhi F., Abdollahi M. Effects of sildenafil on rat irritable bowel syndrome. Therapy (2005) 2 237-242.
19. Sharifzadeh M., Zamanian A.R., Gholizadeh S. et al. Post-training intrahippocampal infusion of nicotine-bucladesine combination causes a synergistic enhancement effect on spatial memory retention in rats. Eur. J. Pharmacol. (2007a) 562 212-220.
20. Neumann S., Bradke F., Tessier-Lavigne M., Basbaum A.I. Regeneration of sensory axons within the injured spinal cord induced by intraganglionic cAMP elevation. Neuron (2002) 34 885-893.
21. Qiu J., Cai D., Dai H. et al. Spinal axon regeneration induced by elevation of cyclic AMP. Neuron (2002) 34 895-903.
22. Hosseini-Zare M.S., Salehi F., Seyedi S.Y. et al. Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice. Eur. J. Pharmacol. (2011) 670 464-470.
23. Brito G.A., Saraiva S.N., Falcao J.L. et al. Dual effect of cAMP on the writhing response in mice. Eur. J. Pharmacol. (2001) 416 223-230.
24. Sharifzadeh M., Aghsami M., Gholizadeh S. et al. Protective effects of chronic lithium treatment against spatial memory retention deficits induced by the protein kinase AII inhibitor H-89 in rats. Pharmacology (2007b) 80 158-165.
25. Sharifzadeh M., Tavasoli M., Naghdi N., Ghanbari A., Amini M., Roghani A. Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats. J. Neurochem. (2005) 95 1078-1090.
26. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinoline sulfonamide, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry (1984) 23 5036-5041.
27. Lochner A., Moolman J.A. The many faces of H89: a review. Cardiovasc. Drug Rev. (2006) 24 261-274.
28. Ivanov A., Aston-Jones G. Local opiate withdrawal in locus coeruleus neurons in vitro. J. Neurophysiol. (2001) 85 2388-2397.
29. Punch L.J., Self D.W., Nestler E.J., Taylor J.R. Opposite modulation of opiate withdrawal behaviors on microinfusion of a protein kinase A inhibitor versus activator into the locus coeruleus or periaqueductal gray. J. Neurosci. (1997) 17 8520-8527.
30. Maldonado R., Valverde O., Garbay C., Roques B.P. Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal. Naunyn Schmiedebergs Arch. Pharmacol. (1995) 352 565-575.
31. Tokuyama S., Feng Y., Wakabayashi H., Ho I.K. Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8. Eur. J. Pharmacol. (1995) 284 101-107.
32. Marshall I., Grahame-Smith D.G. Evidence against a role of brain 5-hydroxytryptamine in the development of physical dependence upon morphine in mice. J. Pharmacol. Exp. Ther. (1971) 179 634-641.
33. Ye Y., Lin Y., Perez-Polo J.R. et al. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J. Immunol. (2008) 181 3515-3523.
34. Tilley D.G., Maurice D.H. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol. Pharmacol. (2002) 62 497-506.
35. Romero A., Hernández L., García-Nogales P., Puig M.M. Deletion of the inducible nitric oxide synthase gene reduces peripheral morphine tolerance in a mouse model of chronic inflammation. Fundam. Clin. Pharmacol. (2010) 24 317-323.
36. Kumar S., Bhargava H.N. Time course of the changes in central nitric oxide synthase activity following chronic treatment with morphine in the mouse: reversal by naltrexone. Gen. Pharmacol. (1997) 29 223-227.
37. Sullivan M.E., Hall S.R., Milne B., Jhamandas K. Suppression of acute and chronic opioid withdrawal by a selective soluble guanylyl cyclase inhibitor. Brain Res. (2000) 859 45-56.
38. Feng P., Meissler J.J. Jr, Adler M.W., Eisenstein T.K. Morphine withdrawal sensitizes mice to lipopolysaccharide: elevated TNF-alpha and nitric oxide with decreased IL-12. J. Neuroimmunol. (2005) 164 57-65.
39. Hao S., Liu S., Zheng X. et al. The role of TNFalpha in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology (2011) 36 664-676.
40. Whitcomb K., Lupica C.R., Rosen J.B., Berman R.F. Adenosine involvement in postictal events in amygdala-kindled rats. Epilepsy Res. (1990) 6 171-179.
41. Ray A., Gulati K., Anand S., Vijayan V.K. Pharmacological studies on mechanisms of aminophylline-induced seizures in rats. Indian J. Exp. Biol. (2005) 43 849-853.
42. Reinstein L.J., Lichtman S.N., Currin R.T., Wang J., Thurman R.G., Lemasters J.J. Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. Hepatology (1994) 19 1445-1452.
43. Hichami A., Boichot E., Germain N., Berdyshev E., Coqueret O., Lagente V. Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-alpha release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors. Mediators Inflamm. (1996) 5 425-428.
44. Buccafusco J.J., Terry A.V. Jr., Shuster L. Spinal NMDA receptor-nitric oxide mediation of the expression of morphine withdrawal symptoms in the rat. Brain Res. (1995) 679 189-199.
45. Oda H., Murayama T., Nomura Y. Inhibition of inducible nitric oxide synthase expression by endothelin in rat glial cells prepared from the neonatal rat brain. J. Neurochem. (1997) 69 669-674.
46. Minghetti L., Nicolini A., Polazzi E., Creminon C., Maclouf J., Levi G. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia. (1997) 19 152-160.
47. Cao J.L., Ding H.L., He J.H., Zhang L.C., Duan S.M., Zeng Y.M. The spinal nitric oxide involved in the inhibitory effect of midazolam on morphine-induced analgesia tolerance. Pharmacol. Biochem. Behav. (2005) 80 493-503.
48. Abdel-Zaher A.O., Hamdy M.M., Aly S.A., Abdel-Hady R.H., Abdel-Rahman S. Attenuation of morphine tolerance and dependence by aminoguanidine in mice. Eur. J. Pharmacol. (2006) 540 60-66.
49. Fan P., Jiang Z., Diamond I., Yao L. Up-regulation of AGS3 during morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and 7 in rat nucleus accumbens/striatal neurons. Mol. Pharmacol. (2009) 76 526-533.
50. Bailey C.P., Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr. Opin. Pharmacol. (2005) 5 60.
51. Degerman E., Belfrage P., Manganiello V.C. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem. (1997) 272 6823-6826.
52. Cho C.H., Cho D.H., Seo M.R., Juhnn Y.S. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp. Mol. Med. (2000) 32 110-114.
53. Smith F.L., Dombrowski D.S., Dewey W.L. Involvement of intracellular calcium in morphine tolerance in mice. Pharmacol. Biochem. Behav. (1999) 62 381-388.
54. Welch S.P., Bass P.P. Modulation of free intracellular calcium levels [(Ca++)i] in brain and spinal cord of morphine-tolerant rats and mice. Pharmacol. Biochem. Behav. (1995) 51 57-63.
55. Guo Y., Wang H.L., Xiang X.H., Zhao Y. The role of glutamate and its receptors in mesocorticolimbic dopaminergic regions in opioid addiction. Neurosci. Biobehav. Rev. (2009) 33 864-873.
56. Riahi E., Mirzaii-Dizgah I., Karimian S.M., Sadeghipour H.R., Dehpour A.R. Attenuation of morphine withdrawal signs by a GABAB receptor agonist in the locus coeruleus of rats. Behav. Brain Res. (2009) 196 11-14.
57. Rath M., Fohr K.J., Weigt H.U. et al. Etomidate reduces glutamate uptake in rat cultured glial cells: involvement of PKA. Br. J. Pharmacol. (2008) 155 925-933.
58. Adolph O., Koster S., Rath M. et al. Rapid increase of glial glutamate uptake via blockade of the protein kinase A pathway. Glia. (2007) 55 1699-1707.
59. Chavez-Noriega L.E., Stevens C.F. Increased transmitter release at excitatory synapses produced by direct activation of adenylate cyclase in rat hippocampal slices. J. Neurosci. (1994) 14 310-317.
60. Gonzalez P., Cabello P., Germany A., Norris B., Contreras E. Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur. J. Pharmacol. (1997) 332 257-262.
61. Noda Y., Nabeshima T. Opiate physical dependence and N-methyl-D-aspartate receptors. Eur. J. Pharmacol. (2004) 500 121-128.
62. Popik P., Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. (1996) 53 791-797.
63. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science (1991) 251 85-87.
64. Widnell K.L., Russell D.S., Nestler E.J. Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro. Proc. Natl. Acad. Sci. USA (1994) 91 10947-10951.
65. Guitart X., Thompson M.A., Mirante C.K., Greenberg M.E., Nestler E.J. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J. Neurochem. (1992) 58 1168-1171.
66. Cho I.J., Woo N.R., Shin I.C., Kim S.G. H89, an inhibitor of PKA and MSK, inhibits cyclic-AMP response element binding protein-mediated MAPK phosphatase-1 induction by lipopolysaccharide. Inflamm. Res. (2009) 58 863-872.
67. Grant M.B., Davis M.I., Caballero S., Feoktistov I., Biaggioni I., Belardinelli L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. Invest. Ophthalmol. Vis. Sci. (2001) 42 2068-2073.
68. Yang S., Alkayed N.J., Hurn P.D., Kirsch J.R. Cyclic adenosine monophosphate response element-binding protein phosphorylation and neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP). Anesth. Analg. (2009) 108 964-970.
69. Su Y., Ryder J., Ni B. Inhibition of A[beta] production and APP maturation by a specific PKA inhibitor. FEBS Lett. (2003) 546 407-410.
70. Pan J., Zhang Q., Zhang Y., Ouyang Z., Zheng Q., Zheng R. Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci. (2005) 77 183-193.
71. Abdel-Zaher A.O., Abdel-Rahman M.S., FM E.L. Blockade of nitric oxide overproduction and oxidative stress by Nigella sativa oil attenuates morphine-induced tolerance and dependence in mice. Neurochem. Res. (2010) 35 1557-1565.
72. Afify E.A., Khedr M.M., Omar A.G., Nasser S.A. The involvement of KATP channels in morphine-induced antinociception and hepatic oxidative stress in acute and inflammatory pain in rats. Fundam. Clin. Pharmacol. (2012) doi: 10.1111/fcp.12004.
73. Hui L., Hong Y., Jingjing Z., Yuan H., Qi C., Nong Z. HGF suppresses high glucose-mediated oxidative stress in mesangial cells by activation of PKG and inhibition of PKA. Free Radic. Biol. Med. (2010) 49 467-473.
74. Eftekharzadeh B., Ramin M., Khodagholi F. et al. Inhibition of PKA attenuates memory deficits induced by beta-amyloid (1-42), and decreases oxidative stress and NF-kappaB transcription factors. Behav. Brain Res. (2012) 226 301-308.
75. Kim H.S., Lim J.Y., Sul D. et al. Neuroprotective effects of the new diterpene, CBNU06 against beta-amyloid-induced toxicity through the inhibition of NF-kappaB signaling pathway in PC12 cells. Eur. J. Pharmacol. (2009) 622 25-31.